Awaiting any published patient trial of unmodified KPV
Watching KdPT mix-ups · compounding rulemaking
Open until “human data” stops meaning a cell dish or a different analogue
KPV
Investigation · Thin
When does a coherent lab story
become a therapy you can counsel?
Alpha-MSH fragment. Coherent mouse anti-inflammatory story. Published patient package empty. Not a recommendation to use, compound, or avoid.
- MoleculeKPV · Lys-Pro-Val · α-MSH C-terminal tripeptide
- ObjectsUnmodified KPV · KdPT analogue · parent α-MSH · cell-line work
- Mechanism themePepT1 uptake · NF-κB (preclinical)
- U.S. statusNot FDA approved
- PlacementThin investigation (not watchlist)
- Evidence maturityPreclinical coherent · patient package empty
Investigation
What is being claimed?
Gut inflammation. IBD. “Leaky gut.” Skin. The anti-inflammatory peptide without the tan. Stacks with BPC-157. “Human data exist.”
People who already know NF-κB or PepT1 often assume the mechanism slide is the clinical argument.
It isn’t.
Investigation
What is actually known?
Mechanism
Three amino acids from the tail of alpha-MSH. In the 2008 Gastroenterology colitis work, KPV entered intestinal cell models through PepT1 and quieted inflammatory signaling. Oral KPV reduced disease severity in mouse colitis models. Orientation, not a labeled therapy.
Human evidence split
Unmodified KPV in people: No published Phase 1, 2, or 3 trial identified. ClinicalTrials.gov returned no registered KPV studies. FDA’s July 2026 briefing stated the agency had not identified any clinical studies or human exposure data for KPV by any route. That emptiness is the clinical fact.
Human cells: Real in vitro work in intestinal, immune, airway, and skin-cell models. Not a patient package.
KdPT analogue: A different tripeptide (Lys-D-Pro-Thr). A European randomized ulcerative-colitis study exists for K(D)PT. Citing it as “the KPV IBD trial” is an identity error.
Parent hormone: Alpha-MSH and melanocortin agonists, including tanning peptides, are a different pharmacology. Do not launder those claims into KPV.
Regulatory
Not FDA-approved. On July 23, 2026, FDA staff recommended against adding KPV to the 503A Bulks List. The Pharmacy Compounding Advisory Committee then voted 8–6 with 1 abstention to recommend inclusion. That vote is advisory. It isn’t approval, and it doesn’t make compounding legal. As of August 2026, rulemaking has not finished, and the legal status has not changed.
Investigation
What remains uncertain?
- Whether unmodified KPV will ever show meaningful benefit in a published human IBD, gut, or skin trial
- How much of the mouse PepT1 story would survive products people actually buy
- Long-term safety without a human database
- Whether compounding rulemaking follows the committee, the staff, or neither
Still open
- KPV, KdPT, or a cell dish?
- Is a coherent mouse story enough for clinic use before any patient trial?
- Keep on the wall, or demote later?
Investigation
Why should an RD care?
Object literacy. KPV, KdPT, alpha-MSH, and BPC-157 are related in conversation, not in evidence. Write the distinction once.
Vote literacy. A committee can recommend compounding eligibility while the human file is still empty. Eligibility, if it ever arrives through rulemaking, still wouldn’t be proof of benefit.
Expectation literacy. If the goal is IBD, skin disease, or gut symptoms, established medical care and nutrition still own those goals.
Thin-evidence counseling. Curious, precise, unfinished.
Usable line: “KPV is a three-amino-acid fragment of a hormone called alpha-MSH. The mouse and cell story for gut inflammation is coherent. There isn’t a published human trial of this peptide for IBD or skin. If someone cites an ulcerative colitis study, check whether they mean KPV or a different analogue called KdPT.”
Current thinking
as of August 2026 · subject to revision
KPV is an alpha-MSH fragment with a coherent preclinical anti-inflammatory story and an empty published package for unmodified use in people. Public conversation often borrows credibility from human cell-line work or from KdPT, a different analogue that had an ulcerative-colitis trial. A July 2026 advisory-committee vote recommended compounding eligibility. That isn’t a human efficacy finding, and it isn’t a change in law. An intelligent stance today is identity-specific, vote-literate, and unwilling to treat NF-κB slides or forum stacks as clinical proof. Placement: thin investigation on the wall, not a watchlist one-liner and not an equalized dossier.
Evidence consulted Open file
Evidence consulted while building this notebook. Not a citation for every sentence.
Primary
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID 18061177
- Preclinical KPV colitis / epithelial / skin literature as mapped in the landscape
- EudraCT 2011-002462-20 · K(D)PT in mild-to-moderate ulcerative colitis (distinct analogue, not KPV)
Regulatory
- FDA Briefing Document · KPV-related bulk drug substances · Jul 23–24, 2026 PCAC · fda.gov/media/193346 (proposes not adding free base or acetate; “has not identified any clinical studies or human exposure data for KPV via any route of administration”)
- FDA Briefing Document Introduction · Jul 23–24, 2026 PCAC · fda.gov/media/193342 (503A three-prong test; FDA proposing all seven peptides not be included)
- FDA meeting page · Jul 23–24, 2026 PCAC · briefing PDFs posted; transcript and minutes not posted as of Aug 11, 2026
- Federal Register API search Aug 11, 2026 · no proposed or final 503A bulks-list rule for these peptides after Jul 1, 2026
- ClinicalTrials.gov API · query “KPV” · no registered studies as of Aug 11, 2026
- WADA 2026 Prohibited List · KPV not named as a specific entry; unapproved peptides may still be a problem for tested athletes
Secondary
- Vote tallies 8–6–1 (KPV, BPC-157, TB-500) and 7–5–2 (MOTS-c): contemporaneous independent coverage (USA Today, Reuters/PharmaExec, RAPS, ABC News, McDermott). FDA has not yet posted official minutes.
Placement trail · Aug 2026. News and forums stayed in research notes only.
Frozen thinking artifact v0.1 · Aug 2026 · thin investigation. KdPT trial not treated as KPV evidence. Not medical advice.